Endothelium-derived hyperpolarizing factor mediates bradykinin-stimulated tissue plasminogen activator release in humans

J Vasc Res. 2014;51(3):200-8. doi: 10.1159/000362666. Epub 2014 Jun 4.

Abstract

Aims: Bradykinin (BK) stimulates tissue plasminogen activator (t-PA) release from human endothelium. Although BK stimulates both nitric oxide and endothelium-derived hyperpolarizing factor (EDHF) release, the role of EDHF in t-PA release remains unexplored. This study sought to determine the mechanisms of BK-stimulated t-PA release in the forearm vasculature of healthy human subjects.

Methods: In 33 healthy subjects (age 40.3 ± 1.9 years), forearm blood flow (FBF) and t-PA release were measured at rest and after intra-arterial infusions of BK (400 ng/min) and sodium nitroprusside (3.2 mg/min). Measurements were repeated after intra-arterial infusion of tetraethylammonium chloride (TEA; 1 µmol/min), fluconazole (0.4 µmol·min(-1)·l(-1)), and N(G)-monomethyl-L-arginine (L-NMMA, 8 µmol/min) to block nitric oxide, and their combination in separate studies.

Results: BK significantly increased net t-PA release across the forearm (p < 0.0001). Fluconazole attenuated both BK-mediated vasodilation (-23.3 ± 2.7% FBF, p < 0.0001) and t-PA release (from 50.9 ± 9.0 to 21.3 ± 8.9 ng/min/100 ml, p = 0.02). TEA attenuated FBF (-14.7 ± 3.2%, p = 0.002) and abolished BK-stimulated t-PA release (from 22.9 ± 5.7 to -0.8 ± 3.6 ng/min/100 ml, p = 0.0002). L-NMMA attenuated FBF (p < 0.0001), but did not inhibit BK-induced t-PA release (nonsignificant).

Conclusion: BK-stimulated t-PA release is partly due to cytochrome P450-derived epoxides and is inhibited by K(+)Ca channel blockade. Thus, BK stimulates both EDHF-dependent vasodilation and t-PA release.

Trial registration: ClinicalTrials.gov NCT00166166.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biological Factors / physiology*
  • Bradykinin / pharmacology*
  • Cytochrome P-450 Enzyme System / metabolism
  • Female
  • Fluconazole / pharmacology
  • Forearm / blood supply
  • Humans
  • Male
  • Middle Aged
  • Nitroprusside / pharmacology
  • Potassium Channels, Calcium-Activated / physiology
  • Regional Blood Flow / drug effects
  • Tetraethylammonium / pharmacology
  • Tissue Plasminogen Activator / metabolism*
  • Vasodilation / drug effects
  • omega-N-Methylarginine / pharmacology

Substances

  • Biological Factors
  • Potassium Channels, Calcium-Activated
  • endothelium-dependent hyperpolarization factor
  • Nitroprusside
  • omega-N-Methylarginine
  • Tetraethylammonium
  • Fluconazole
  • Cytochrome P-450 Enzyme System
  • Tissue Plasminogen Activator
  • Bradykinin

Associated data

  • ClinicalTrials.gov/NCT00166166